Immunological Aspects of Thrombotic Thrombocytopenic Purpura (TTP): Characterisation of B and T Lymphocytes Specific for the ADAMTS13 Autoantigen and Therapeutic Implications

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

The general objective of the proposed project is to characterise phenotypically and functionally ADAMTS13-specific memory B lymphocytes and autoreactive T lymphocytes, in particular follicular helper T lymphocytes, in the acute phase of the disease, but also during its progression after treatment. The aim is to highlight their contribution to the initial pathogenic process, their evolution under treatment, and also their involvement in patients who are refractory to immunosuppressive therapies and during relapses. The aim of this project is to identify early phenotypic or functional parameters that are predictive of relapse and that can be used for personalised optimisation of treatment to maintain remission.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• age over 18

• patients with TTP at any stage of diagnosis (acute phase, lasting remission or not, relapse)

• patients undergoing internal medicine at Rouen University Hospital

• people who have read and understood the information letter

• membership of a social security scheme

Locations
Other Locations
France
University Rouen Hospital,
RECRUITING
Rouen
Contact Information
Primary
David DM MALLET, Director
david.mallet@chu-rouen.fr
02 32 88 82 65
Backup
Vincent VF FERRANTI, ARC
vincent.ferranti@chu-rouen.fr
02 32 88 82 65
Time Frame
Start Date: 2023-05-11
Estimated Completion Date: 2027-05-11
Participants
Target number of participants: 44
Treatments
Group 1: patients in the acute phase of TTP
Consultation or hospitalisation when TTP is diagnosed, before treatment is initiated
Groupe 2 : patient in durable remission with ADAMTS13 activity > 10%.
Follow-up consultation
Groupe 3 : patient in remission with ADAMTS13 activity < 10%.
Follow-up consultation before initiation of pre-emptive treatment
Group 4: relapsing patients
Consultation or hospitalisation at the time of relapse, before treatment is initiated
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Rouen

This content was sourced from clinicaltrials.gov

Similar Clinical Trials